Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082503 | 0.85 | ACHE (0.46) | ACHEHTR2AHTR1AHTR7DRD3 | |
| SCHEMBL15700104 | 0.85 | HTR2A (0.46) | ACHEHTR2AHTR1AHTR7DRD3 | |
| SCHEMBL1451967 | 0.81 | ACHE (0.51) | ACHEHTR2AHTR1AHTR7DRD3 | |
| SCHEMBL8854199 | 0.79 | ACHE (0.50) | ACHEHTR2AHTR1AHTR7DRD3 | |
| SCHEMBL27081924 | 0.79 | ACHE (0.39) | ACHEHTR2AHTR1AHTR7DRD3 | |
| SCHEMBL20657105 | 0.79 | LTA4H (0.51) | ACHEHTR2AHTR1AHTR7DRD3 | |
| Hydrochloric Acid SCHEMBL6764862 | 0.77 | ACHE (0.49) | ACHEHTR2AHTR1AHTR7DRD3 | |
| Hydrochloric Acid SCHEMBL6764859 | 0.77 | ACHE (0.49) | ACHEHTR2AHTR1AHTR7DRD3 | |
| SCHEMBL21694390 | 0.74 | ACHE (0.49) | ACHEHTR2AHTR1AHTR7DRD3 | |
| SCHEMBL577446 | 0.73 | HTR1A (0.57) | ACHEHTR2AHTR1AHTR7DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100484973-C | Substituted indenyl metal complexes and polymerization process | DOW GLOBAL TECHNOLOGIES INC (US) | 2009-05-06 | — | — | CN | disclosed |
| EP-1487886-B1 | SUBSTITUTED INDENYL METAL COMPLEXES AND POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7098356-B2 | Substituted indenyl metal complexes and polymerization process | DOW GLOBAL TECHNOLOGIES INC. (US) | 2006-08-29 | — | — | US | disclosed |
| CN-1643004-A | Substituted indenyl metal complexes and polymerization process | DOW GLOBAL TECHNOLOGIES INC (US) | 2005-07-20 | — | — | CN | disclosed |
| US-20050143536-A1 | Substituted indenyl metal complexes and polymerization process | DOW GLOBAL TECHNOLOGIES LLC | 2005-06-30 | — | — | US | disclosed |
| EP-1487886-A1 | SUBSTITUTED INDENYL METAL COMPLEXES AND POLYMERIZATION PROCESS | Dow Global Technologies Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078483-A1 | SUBSTITUTED INDENYL METAL COMPLEXES AND POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143536-A1 | Substituted indenyl metal complexes and polymerization process | ORC3, SOD1, YAP1 | ACHE 4196/4885HTR2A 2363/4885HTR1A 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.